Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pacira BioSciencesPCRX -0.88%81 Shiller PE Ratio is 146.47 as of Sep. 04, 2026, which is 25% below its 10-year median of 194.00. GuruFocus rates PCRX with a GF Score™ of 81/100 and a GF Value™ of $29.27 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 525 Drug Manufacturers companies, Pacira BioSciences ranks worse than 96.38% on this metric.
The historical rank and industry rank for Pacira BioSciences's Shiller PE Ratio or its related term are showing as below:
PCRX'
s Shiller PE Ratio Range Over the Past 10 Years
Min: 30 Med: 194 Max: 500.88
Current: 146.47
During the past years, Pacira BioSciences's highest Shiller PE Ratio was 500.88. The lowest was 30.00. And the median was 194.00.
PCRX's Shiller PE Ratio is ranked worse than 96.38% of 525
companies
in the Drug Manufacturers industry
Industry Median: 25.41
vs PCRX: 146.47
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.
Pacira BioSciences's adjusted earnings per share data for the three months ended in Jun. 2026 was $0.120. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is $0.18 for the trailing ten years ended in Jun. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Pacira BioSciences (NAS:PCRX) Shiller PE Ratio Explanation
Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.
Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.
Be Aware
Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.
Pacira BioSciences Shiller PE Ratio Related Terms
Pacira BioSciences Shiller PE Ratio Historical Data
* Premium members only.
The historical data trend for Pacira BioSciences's Shiller PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PCRX vs AMPH, COLL, IRWD: Shiller PE Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Pacira BioSciences's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pacira BioSciences Shiller PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pacira BioSciences's Shiller PE Ratio distribution charts can be found below:
* The bar in red indicates where Pacira BioSciences's Shiller PE Ratio falls into.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Add all the adjusted EPS together and divide 10 will get our E10.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Pacira BioSciences (PCRX) has a Shiller PE Ratio of 146.47 as of Sep. 04, 2026. Shiller price-earnings ratio is the ratio of share price to a company's inflation-adjusted earnings over a 10-year period. View historical data on Pacira BioSciences and its competitors. This is 25% below median its historical median of 194.00. Over the past decade, Pacira BioSciences' Shiller PE Ratio has ranged from 30.00 to 500.88. According to the industry distribution chart, Pacira BioSciences ranks #506 out of 525 companies in the Drug Manufacturers industry, placing it in the top 96.4%.
Is Pacira BioSciences' Shiller PE Ratio too high?
Pacira BioSciences' current Shiller PE Ratio of 146.47 is 25% below median its 10-year median of 194.00. Over the past 10 years, this metric has ranged from a low of 30.00 to a high of 500.88. The Drug Manufacturers industry median Shiller PE Ratio is 25.41. Pacira BioSciences' value of 146.47 is 476.4% above this industry median. Based on the distribution chart, Pacira BioSciences ranks #506 out of 525 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Pacira BioSciences has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pacira BioSciences' Shiller PE Ratio compare to AMPH and COLL?
According to the Drug Manufacturers industry distribution chart, Pacira BioSciences ranks #506 out of 525 companies for Shiller PE Ratio. This places Pacira BioSciences in the lower half of its industry. The industry median Shiller PE Ratio is 25.41. Pacira BioSciences' value of 146.47 is 476.4% above this benchmark. Historically, Pacira BioSciences' own Shiller PE Ratio has ranged from 30.00 to 500.88 over the past decade. While the company's 10-year median is 194.00 vs. the industry median of 25.41, Pacira BioSciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shiller PE Ratio for a Drug Manufacturers company?
The median Shiller PE Ratio among Drug Manufacturers companies is 25.41, based on 525 companies in the industry. Companies in the top quartile (top 25%) have a Shiller PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Shiller PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pacira BioSciences's current Shiller PE Ratio of 146.47 is 476.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shiller PE Ratio mean?
A high Shiller PE Ratio can signal that a stock is expensive relative to its fundamentals. Shiller price-earnings ratio is the ratio of share price to a company's inflation-adjusted earnings over a 10-year period. View historical data on Pacira BioSciences and its competitors. For the Drug Manufacturers industry, the median Shiller PE Ratio is 25.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pacira BioSciences's current Shiller PE Ratio is 146.47, which is 25% below median its own 10-year median of 194.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacira BioSciences stock overvalued right now?
Based on GuruFocus' analysis, Pacira BioSciences (PCRX) is currently considered Modestly Undervalued. The stock's GF Value™ is $29.27, compared to a current price of $26.37 — trading 9.9% below its estimated fair value. The current Shiller PE Ratio is 146.47, which is 25% below median its 10-year median of 194.00 and 476.4% above the Drug Manufacturers industry median of 25.41. Pacira BioSciences' overall GF Score™ is 81/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shiller PE Ratio calculated?
Shiller PE Ratio is calculated from a company's financial statements. For Pacira BioSciences (PCRX), the current Shiller PE Ratio is 146.47 as of Sep. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pacira BioSciences (PCRX) Overvalued in 2026?
Based on GuruFocus' analysis, Pacira BioSciences stock appears to be undervalued.
The current stock price of $26.37 is trading 9.9% below its estimated GF Value™ of $29.27.
GuruFocus considers Pacira BioSciences to be Modestly Undervalued.
Key valuation signals for PCRX:
Shiller PE Ratio: 146.47 (25% below median its 10-year median of 194.00)
GF Value™: $29.27 vs. price of $26.37 (9.9% below fair value)
Industry Position: 476.4% above the Drug Manufacturers median (#506 of 525)
No single metric tells the full story. See the PCRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
81GF Score
Get the complete analysis for PCRX
Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PCRX has been successfully added to your 
